Posted on by ScienceFather
53 / 100
Powered by Rank Math SEO

Luigi Rigacci : Ematologia

Luigi Rigacci, a seasoned hematologist, embarked on his medical journey at the School of Medicine from 1981 to 1989. He later specialized in Hematology in 1990-1992, marking the beginning of a distinguished career. Between 1999 and 2018, he dedicated his expertise to the Hematology Department of Azienda Ospedaliero-Universitaria Careggi in Firenze. In 2018, he assumed the role of Chief of the Hematology and Stem Cell Transplantation Unit at San Camillo Hospital in Rome. As of 2022, Luigi Rigacci serves as a Researcher at Campus Bio-Medico University and holds the position of Chief of Hematology and Stem Cell Transplantation Unit at Fondazione Policlinico Universitario Campus Bio-Medico, Rome. 🩸

professional profiles:

scopus profile 

orcid profile 

google scholar

Education:

Luigi Rigacci embarked on his medical journey from 1981 to 1989 at the School of Medicine, laying the foundation for a remarkable career. His commitment led him to specialize in Hematology from 1990 to 1992, honing his expertise in blood-related disorders. This dedicated period of specialization marked the beginning of his impactful contributions to the field. 🩸 Luigi Rigacci’s formative years in the School of Medicine, coupled with his focused Hematology specialization, set the stage for a career marked by excellence and advancements in the understanding and treatment of hematological conditions.

INSTITUTION AND POSITION TITLE:

Luigi Rigacci, a distinguished researcher at Campus Bio-Medico University in Rome, stands at the forefront of medical innovation. As the Director of the Hematology and Stem Cell Transplantation Unit at the Department of Medicine and Surgery, Università Campus Bio-Medico Roma, he orchestrates groundbreaking advancements in healthcare. 🏥 His leadership extends to the Fondazione Policlinico Universitario Campus Bio-Medico, solidifying his commitment to cutting-edge medical practices. Rigacci’s pivotal role in both institutions reflects his passion for advancing hematology and stem cell transplantation, contributing significantly to the medical community’s progress and patient care.

Awards And Honors:

Luigi Rigacci stands as a Founding Member of the Fondazione Italiana Linfomi (FIL), showcasing his unwavering dedication to lymphoma research and advocacy. 🇮🇹 His visionary role in establishing FIL underscores a commitment to advancing scientific understanding, patient support, and innovative solutions in the field of lymphomas. Rigacci’s leadership as a Founding Member reflects a profound influence on the organization’s mission to enhance collaboration, fund crucial research initiatives, and improve the lives of individuals affected by lymphomas. His involvement exemplifies a steadfast commitment to shaping the future landscape of lymphoma care and fostering a sense of community within the foundation.

Major Research Interests:

Luigi Rigacci is an eminent figure in the medical realm, specializing in the comprehensive diagnosis, treatment, and management of lymphoproliferative diseases. With a particular focus on both Hodgkin and non-Hodgkin lymphomas, Rigacci has devoted his expertise to advancing the understanding and care of these complex conditions. Additionally, his proficiency extends to the diagnosis, treatment, and management of chronic lymphoproliferative diseases, showcasing a holistic approach to patient well-being. Rigacci’s contributions in these critical areas underscore his commitment to providing optimal medical solutions, improving patient outcomes, and shaping the landscape of lymphoproliferative disease management.

Research Focus:

The author of the cited study “Clinical Characteristics and Risk Factors Associated with COVID-19 Severity in Patients with Haematological Malignancies in Italy: A Retrospective, Multicentre, Cohort Study” (Cited: 512 | Year: 2020) primarily focuses on research related to the impact of COVID-19 on patients with hematological malignancies. Their work delves into the clinical characteristics and risk factors influencing the severity of COVID-19 in this specific patient population. This study contributes valuable insights to the intersection of hematology and infectious diseases, aiding in the understanding of unique challenges faced by individuals with hematological malignancies during the COVID-19 pandemic. 🩸🔬📊

Publication:

 

 

Luigi Rigacci | Ematologia | Best Paper Award

You May Also Like